Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National US Cohort of US Military Veterans with Inflammatory Bowel Disease

被引：0
|
作者：
Hou, J. K. [1 ]
Pham, C. [2 ]
Sansgiry, S. [3 ]
Modi, V. [2 ]
Waljee, A. K. [4 ]
机构：
[1] Baylor Coll Med, Sect Gastroenterol, 5207 Contour Pl, Houston, TX USA
[2] Baylor Coll Med, Med, Houston, TX USA
[3] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Med, Houston, TX USA
[4] Ann Arbor VA Univ Michigan, Med, Ann Arbor, VA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P750
引用
收藏
页码：880 / 881
页数：2
相关论文
共 50 条
  • [21] Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration
    Patel, Shardool
    Walsh, Jessica
    Pinnell, Derek
    Pei, Shaobo
    Chen, Wei
    Rojas, Jorge
    Rathod, Anitha
    Johnson, Jessica
    Gawron, Andrew
    Curtis, Jeffrey R.
    Baker, Joshua F.
    Cannon, Grant W.
    Wu, David
    Lai, Miao
    Sauer, Brian C.
    MEDICINE, 2024, 103 (37)
  • [22] INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: CLINICAL OUTCOMES IN REAL-WORLD PATIENTS FROM THE DANBIO REGISTRY
    Nabi, H.
    Hetland, M. L.
    Loft, A. G.
    Hendricks, O.
    Jensen, D.
    Pedersen, J. K.
    Just, S. A.
    Danebod, K.
    Munk, H. L.
    Kristensen, S.
    Manilo, N.
    Colic, A.
    Linauskas, A.
    Thygesen, P. H.
    Christensen, L. B.
    Kalisz, M. Hogberget
    Lomborg, N.
    Grydehoj, J.
    Raun, J.
    Ahmed, R.
    Mehnert, F.
    Krogh, N. Steen
    Glintborg, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 45 - 46
  • [23] Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts
    Moura, C. S.
    Lukusa, L.
    Wong, E. C.
    Lakatos, P. L.
    Afif, W.
    Narula, N.
    Bernatsky, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I293 - I293
  • [24] Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study
    Jose Casanova, Maria
    Nantes, Oscar
    Varela, Pilar
    Vela-Gonzalez, Milagros
    Rivero, Montserrat
    Sierra-Gabarda, Olivia
    Riestra, Sabino
    Barreiro-de Acosta, Manuel
    del Mar Martin-Rodriguez, Maria
    Jerusalen Gargallo-Puyuelo, Carla
    Reygosa, Cristina
    Munoz, Roser
    Garcia de la Filia-Molina, Irene
    Nunez-Ortiz, Andrea
    Kolle, Lilyan
    Calafat, Margalida
    Maria Huguet, Jose
    Iglesias-Flores, Eva
    de Jesus Martinez-Perez, Teresa
    Bosch, Orencio
    Maria Duque-Alcorta, Jose
    Frago-Larramona, Santiago
    Van Domselaar, Manuel
    Manuel Gonzalez-Cosano, Victor
    Bujanda, Luis
    Rubio, Saioa
    Mancebo, Alejo
    Castro, Beatriz
    Garcia-Lopez, Santiago
    de Francisco, Ruth
    Nieto-Garcia, Laura
    Laredo, Viviana
    Gutierrez-Casbas, Ana
    Mesonero, Francisco
    Leo-Carnerero, Eduardo
    Canete, Fiorella
    Ruiz, Lucia
    Gros, Beatriz
    del Moral-Martinez, Maria
    Rodriguez, Cristina
    Chaparro, Maria
    Gisbert, Javier P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (01) : 60 - 70
  • [25] The Incidence and Prevalence of Anxiety, Depression, and PTSD Among a National Cohort of US Veterans With Inflammatory Bowel Disease
    Thakur, Elyse R.
    Waljee, Akbar K.
    Gaidos, Jill
    Feagins, Linda A.
    Govani, Shail M.
    Sansgiry, Shubhada
    Kramer, Jennifer R.
    Dindo, Lilian
    El-Serag, Hashem B.
    Hou, Jason K.
    GASTROENTEROLOGY, 2016, 150 (04) : S567 - S567
  • [26] Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)
    Bokemeyer, Bernd
    Hlavaty, Tibor
    Allez, Matthieu
    Selema, Pamela
    Moosavi, Shahrzad
    Cadatal, Mary Jane
    Fowler, Heather
    Mueller, Markus
    Liau, Katherine F.
    Gisbert, Javier P.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 791 - 800
  • [27] Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
    Plevris, N.
    Chuah, C. S.
    Allen, R. M.
    Arnott, I. D.
    Brennan, P. N.
    Chaudhary, S.
    Churchhouse, A. M. D.
    Din, S.
    Donoghue, E.
    Gaya, D. R.
    Groome, M.
    Jafferbhoy, H. M.
    Jenkinson, P. W.
    Lam, W. L.
    Lyons, M.
    Macdonald, J. C.
    MacMaster, M.
    Mowat, C.
    Naismith, G. D.
    Potts, L. F.
    Saffouri, E.
    Seenan, J. P.
    Sengupta, A.
    Shasi, P.
    Sutherland, D. I.
    Todd, J. A.
    Veryan, J.
    Watson, A. J. M.
    Watts, D. A.
    Jones, G. R.
    Lees, C. W.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (09): : 1111 - 1120
  • [28] The Incidence and Prevalence of Anxiety, Depression, and Posttraumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease
    Thakur, Elyse R.
    Sansgiry, Shubhada
    Kramer, Jennifer R.
    Waljee, Akbar K.
    Gaidos, Jill K.
    Feagins, Linda A.
    Govani, Shail M.
    Dindo, Lilian
    El-Serag, Hashem B.
    Hou, Jason K.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (09) : 1423 - 1428
  • [29] Calibrating real-world evidence studies against randomized trials: Treatment effectiveness of infliximab in inflammatory bowel disease
    Kirchgesner, Julien
    Desai, Rishi J.
    Schneeweiss, Maria C.
    Beaugerie, Laurent
    Kim, Seoyoung C.
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 41 - 42
  • [30] Obesity and Associated Adverse Health Outcomes Among US Military Members and Veterans: Findings from the Millennium Cohort Study
    Rush, Toni
    LeardMann, Cynthia A.
    Crum-Cianflone, Nancy F.
    OBESITY, 2016, 24 (07) : 1582 - 1589
12345